Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival

Table 1 Comparison of clinicopathological findings by existence of liver metastases

		Patients with liver metastases n = 69 (cases)	Patients without liver metastases n = 70 (cases)	pvalue
Gender	M/F	40/29	38/32	N.S.
Age	Years	60.7 ± 9.9	62.5 ± 10.1	N.S.
TNM stage	I/II/III/IV	0/12/23/34	11/38/21/0	< 0.01^a
Tumour site	C/R	45/24	49/21	N.S.
LN mets	Yes/No	41/28	31/39	N.S.
Differentiation	w/mod/por	37/30/2	21/33/16	N.S.
Liver mets	Sync/Meta	23/46	N.A.	N.A.
No. of liver mets	Solo/Multi	38/31	N.A.	N.A.
PTEN expression	S/W	17/52	44/26	< 0.01^a
Median follow-up	Months	35.5 ± 27.4	37.2 ± 39.9	N.S.
5-year survival	(%)	34.3	79.2	< 0.01^b

LN, lymph node; mets, metastasis; M, male; F, female; C, colon; R, rectum; w, well differentiated adenocarcinoma; mod, moderately differentiated adenocarcinoma; por, poorly differentiated adenocarcinoma; Sync, synchronous metastasis; Meta, metachronous metastasis; Solo, solitary metastasis; Multi, multiple metastases; S, strong; W, weak; N.A., not applicable; N.S., not significant. The ^a p-values were obtained using the Mann-Whiteny U test. The ^b p-values were obtained using Kaplan-Meier survival curves based on PTEN expression tested with the Wilcoxon test. Values of age are given mean ± s.d. N.S., not significant.